Abstract
Objective:
To investigate the expression and prognostic value of miR-224 expression in patients with diffuse large B-cell lymphoma (DLBCL) who underwent R-CHOP.
Materials and methods:
RT-PCR was used to determine the relative expression of miR-224, in 258 DLBCL patients and 40 normal lymphoid tissue specimens.
Results:
MiR-224 expression in DLBCL patients was significantly down-regulated compared to that in negative controls (p < 0.05). The 5-year progression-free survival and overall survival rates were significantly higher in the high-expression level group compared to the low-expression level group (p < 0.05).
Conclusions:
MiR-224 expression level is implicated as a prognostic marker for DLBCL patients treated with R-CHOP.
Keywords:
Biomarkers; R-CHOP; diffuse large B-cell lymphoma; microRNA.
MeSH terms
-
Adolescent
-
Adult
-
Aged
-
Aged, 80 and over
-
Antibodies, Monoclonal, Murine-Derived / administration & dosage
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Biomarkers, Tumor / genetics
-
Cyclophosphamide / administration & dosage
-
Doxorubicin / administration & dosage
-
Female
-
Gene Expression Regulation, Neoplastic*
-
Humans
-
Kaplan-Meier Estimate
-
Lymphoma, Large B-Cell, Diffuse / drug therapy*
-
Lymphoma, Large B-Cell, Diffuse / genetics*
-
Lymphoma, Large B-Cell, Diffuse / pathology
-
Male
-
MicroRNAs / genetics*
-
Middle Aged
-
Neoplasm Staging
-
Prednisone / administration & dosage
-
Prognosis
-
Reverse Transcriptase Polymerase Chain Reaction
-
Treatment Outcome
-
Vincristine / administration & dosage
-
Young Adult
Substances
-
Antibodies, Monoclonal, Murine-Derived
-
Biomarkers, Tumor
-
MIRN224 microRNA, human
-
MicroRNAs
-
Vincristine
-
Doxorubicin
-
Cyclophosphamide
-
Prednisone